An Austin biotech company is laying off a third of its staff following news that its primary drug candidate didn't produce ...

Effectively treating and preventing this common form of dementia will require a cocktail of drugs and a combination of ...

Researchers found that combining cardiovascular disease drug classes, particularly antihypertensives, can reduce risk of dementia.

We recently published a list of Jim Cramer Discussed These 10 NASDAQ 100 Stocks Recently. In this article, we are going to ...

Furthermore, the cabinet approved the imposition of Green Energy Development Charges for Pumped Storage Projects. A charge of ...

Anavex Life Sciences' ANAVEX 2-73 shows promise in treating Alzheimer's, with strong efficacy in slowing cognitive and ...

One of the most intriguing is a late-stage trial of semaglutide in Alzheimer’s patients ... with the drugs available at a large discount to the list price. Side-effects including nausea ...

Lilly’s solanezumab famously failed to produce significant results in early stage Alzheimer’s late last year, the latest in a long list of drugs that have come up short in trials. George ...

Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, ...

Although we don't know a lot about the causes of Alzheimer's disease, the following conditions may raise your risk.

The co-developer of a US-approved drug, Professor Andrew Wilks has formed Synthesis Bioventures to sniff out more winners.

One of the most intriguing is a late-stage trial of semaglutide in Alzheimer’s patients ... with the drugs available at a large discount to the list price. Side-effects including nausea ...